Interim FDA-Mandated Postmarket Study Finds Essure Has Significantly Higher Rates Of Adverse Events
Executive Summary
As expected based on retrospective data, new results from an ongoing postmarket study has found Bayer’s Essure birth control device has significantly higher rates of major adverse events compared to women who undergo tubal ligation.
You may also be interested in...
Social Media Posts Showed Almost 1,500 Adverse Events, 53 Deaths Linked To Essure: FDA Report
Report quantifies social media posts describing adverse events involving the Essure contraceptive device, which was pulled from the market amid safety concerns.
FDA Report: Pain, Menstrual Issues Most Common Essure-Tied Adverse Events
The US agency has released data on nearly 50,000 adverse events related to Bayer’s withdrawn Essure birth control implant.
Essure Update: Almost All Unsold Units Back To Bayer; Postmarket Study Enrollment Complete
The US FDA says Bayer has successfully recovered unsold Essure units and completed enrollment in a Sec. 522 postmarket study, fulfilling deadlines set at a year from the date the devices were taken off the US market.